Retrospective evaluation of plasma protein tumour markers for early lung cancer detection

Davies, Michael Peter Alan ORCID: 0000-0002-7609-4977, Kolamunnage-Dona, Ruwanthi ORCID: 0000-0003-3886-6208, Phillips, Suzannah, Lambert, Angela, Tate, Stephanie and Field, John Kirkpatrick ORCID: 0000-0003-3951-6365 (2024) Retrospective evaluation of plasma protein tumour markers for early lung cancer detection BJC Reports, 2 (1). 59-. ISSN 2731-9377, 2731-9377

PDF Davies_et_al-2024-BJC_Reports Plasma TM.pdf - Open Access published version Download (693kB) | Preview

Abstract

Abstract Background Blood-based biomarkers might help lung cancer diagnosis. A panel of serum tumour markers (TM) has been validated for hospital referrals due to clinical suspicion of lung cancer. We have compared plasma from a cohort enriched for early-stage lung cancer, including controls from a healthy population cohort. Methods TM assays for CEA, CYFRA 21-1, CA15.3, ProGRP and SCC were run on a Roche Elecsys 2010 Immunoassay Analyser for a retrospective, nested case-control cohort from the Liverpool Lung Project. The primary endpoints were the sensitivity and specificity of a pre-defined TM panel using published thresholds. Results Except for ProGRP, TM levels were significantly higher in cases and ROC AUC values demonstrated significant discriminant power. Accuracy and levels were higher for late-stage cancers, except for ProGRP which was highest in stage 1 cancers. Although providing similar sensitivity (82.4% vs 88.5%), TMs performed worse for specificity (39.3% vs 82%) and overall (Youden’s Index 0.22 vs 0.77) and this was not improved by threshold optimisation or binary logistic regression. Conclusions Although the TMs were associated with lung cancer status and discriminatory with a high sensitivity when combined, performance was compromised in early-stage disease, which casts some doubt on utility in the screening setting.

Item Type:	Article
Uncontrolled Keywords:	32 Biomedical and Clinical Sciences, 3211 Oncology and Carcinogenesis, Lung Cancer, Clinical Research, Cancer, Prevention, Lung, 4.1 Discovery and preclinical testing of markers and technologies, Cancer
Depositing User:	Symplectic Admin
Date Deposited:	09 Sep 2024 07:32
Last Modified:	23 Dec 2025 19:17
DOI:	10.1038/s44276-024-00082-6
Related Websites:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3184364
Disclaimer:	The University of Liverpool is not responsible for content contained on other websites from links within repository metadata. Please contact us if you notice anything that appears incorrect or inappropriate.